# Curanex Pharmaceuticals Inc (CURX) · Edgar & Edgarette company card

> Figures from the company's own SEC filings.

SEC CIK 2025942 · fiscal year ended — · 0 audited years read · [page](https://www.pops4.com/boards/company/CURX) · [JSON](https://www.pops4.com/boards/company/CURX.json)

## Figures, as filed in the 10-K

| Measure | Value |
|---|---|
| Revenue | — |
| Revenue growth, 1 year | — |
| Revenue growth per year | — |
| Operating margin | — |
| Net margin | — |
| Operating cash flow | — |
| Capital spending | — |
| Free cash flow | — |
| Cash | — |
| Long-term debt | — |
| Total assets | — |
| Total equity | — |
| Equity ÷ assets | — |
| Return on equity | — |
| Dividend per share | — |
| Dividend years rising | — |

## Readings, computed from those figures


## Edgarette's reading

The filings carry no annual revenue line Edgarette can read (common for banks and insurers, which report income differently). Nothing weighed, nothing guessed.

## Health Watch, last 12 months

- Item 3.01 Exchange listing notice or transfer: 1, latest 2025-11-06 ([filing](https://www.sec.gov/Archives/edgar/data/2025942/000149315225021028/0001493152-25-021028-index.htm))
- Item NT 10-Q Late quarterly report notice: 1, latest 2025-11-17 ([filing](https://www.sec.gov/Archives/edgar/data/2025942/000149315225023703/0001493152-25-023703-index.htm))
- Item 5.02 Director or officer change: 2, latest 2026-03-06 ([filing](https://www.sec.gov/Archives/edgar/data/2025942/000149315226009155/0001493152-26-009155-index.htm))

## Recent filings

- 8-K · filed 2026-10-19 · 8.01 Other Events · [filing](https://www.sec.gov/Archives/edgar/data/2025942/000149315226047614/0001493152-26-047614-index.htm)
- 8-K · filed 2026-09-04 · 8.01 Other Events · [filing](https://www.sec.gov/Archives/edgar/data/2025942/000149315226041546/0001493152-26-041546-index.htm)
- 8-K · filed 2026-08-17 · 3.03 Material Modifications to Rights of Security Holders; 5.03 Amendments to Articles or Bylaws; Change in Fiscal Year; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/2025942/000149315226038764/0001493152-26-038764-index.htm)
- 10-Q · filed 2026-08-14 · [filing](https://www.sec.gov/Archives/edgar/data/2025942/000149315226038145/0001493152-26-038145-index.htm)
- 8-K · filed 2026-05-14 · 7.01 Regulation FD Disclosure; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/2025942/000149315226022898/0001493152-26-022898-index.htm)
- 10-Q · filed 2026-05-14 · [filing](https://www.sec.gov/Archives/edgar/data/2025942/000149315226022892/0001493152-26-022892-index.htm)

## Sources

- facts: https://data.sec.gov/api/xbrl/companyfacts/CIK0002025942.json
- filings: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=2025942

## Cite

POPS4, Edgar & Edgarette: Curanex Pharmaceuticals Inc (CURX) company card, from the company's own SEC filings, accessed 2026-11-04, https://www.pops4.com/boards/company/CURX. CC BY 4.0. For a figure, add the filing URL under filings or sources.

DOI https://doi.org/10.5281/zenodo.23672509 · catalog https://www.pops4.com/boards/catalog.json · Figures as filed with the SEC. Card text CC BY 4.0, POPS4.

Reporting, not investment advice. No price targets and no trading recommendations.